This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Humphrey, R. W. Articles by Yarchoan, R. Search for Related Content PubMed PubMed Citation Articles by Humphrey, R. W. Articles by Yarchoan, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1997, 1017-1023, Vol 41, No. 5
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology

RW Humphrey, A Ohagen, DA Davis, T Fukazawa, H Hayashi, S Hoglund, H Mitsuya and R Yarchoan
HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

The processing of gag and gag-pol polyproteins by human immunodeficiency virus type 1 (HIV-1) protease is a crucial step in the formation of infectious HIV-1 virions. In this study, we examine whether particles produced in the presence of inhibitors of HIV-1 protease can subsequently undergo gag polyprotein cleavage with restoration of infectivity following removal of the inhibitors. Viral particles produced during 7 days of culture in the presence of the protease inhibitors KNI-272 (10 microM) and saquinavir (5 microM) contained predominantly p55gag polyprotein but little or no p24gag cleavage product. Following resuspension of the particles in medium free of the inhibitor, some gag polyprotein processing was detected in particles produced from the KNI-272-treated cells, but not from the saquinavir-treated cells within the first 3 h. However, the majority of the protein remained as p55gag throughout a 48-h experimental period. The infectivity (50% tissue culture infective dose per milliliter) of the viral particles from KNI-272-treated cells was 10(6)-fold lower than that of control particles and did not significantly increase over the 48 h after the inhibitor was removed, despite the apparent return of protease function in a subset of these virions. This failure to restore infectivity was due neither to a reduction in the number of particles produced by protease inhibitor-treated cells nor to a failure of HIV RNA to be packaged in the virions. These particles also failed to express the mature phenotype by electron microscopy. Thus, while some processing of the gag polyprotein can occur in isolated HIV virions, this does not appear to be sufficient to restore infectivity in the majority of particles. This finding suggests that there may be constraints on postbudding polyprotein processing in the production of viable particles. These results should have positive implications regarding the use of protease inhibitors as anti-HIV drugs.

This article has been cited by other articles:

• Davis, D. A., Read-Connole, E., Pearson, K., Fales, H. M., Newcomb, F. M., Moskovitz, J., Yarchoan, R. (2002). Oxidative Modifications of Kynostatin-272, a Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor: Potential Mechanism for Altered Activity in Monocytes/Macrophages. Antimicrob. Agents Chemother. 46: 402-408 [Abstract] [Full Text]  
• Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B. (2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev. 64: 725-745 [Abstract] [Full Text]  
• Speck, R. R., Flexner, C., Tian, C.-J., Yu, X.-F. (2000). Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors. Antimicrob. Agents Chemother. 44: 1397-1403 [Abstract] [Full Text]  
• Davis, D. A., Yusa, K., Gillim, L. A., Newcomb, F. M., Mitsuya, H., Yarchoan, R. (1999). Conserved Cysteines of the Human Immunodeficiency Virus Type 1 Protease Are Involved in Regulation of Polyprotein Processing and Viral Maturation of Immature Virions. J. Virol. 73: 1156-1164 [Abstract] [Full Text]  
• Davis, D. A., Newcomb, F. M., Starke, D. W., Ott, D. E., Mieyal, J. J., Yarchoan, R. (1997). Thioltransferase (Glutaredoxin) Is Detected Within HIV-1 and Can Regulate the Activity of Glutathionylated HIV-1 Protease in Vitro. J. Biol. Chem. 272: 25935-25940 [Abstract] [Full Text]